180 related articles for article (PubMed ID: 22354724)
21. Telomerase-specific oncolytic adenovirus expressing TRAIL suppresses peritoneal dissemination of gastric cancer.
Zhou W; Dai S; Zhu H; Song Z; Cai Y; Lee JB; Li Z; Hu X; Fang B; He C; Huang X
Gene Ther; 2017 Apr; 24(4):199-207. PubMed ID: 28075429
[TBL] [Abstract][Full Text] [Related]
22. Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.
Shashkova EV; Kuppuswamy MN; Wold WS; Doronin K
Cancer Gene Ther; 2008 Feb; 15(2):61-72. PubMed ID: 17992200
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models.
Guiho R; Biteau K; Grisendi G; Chatelais M; Brion R; Taurelle J; Renault S; Heymann D; Dominici M; Redini F
Cytotherapy; 2018 Aug; 20(8):1037-1045. PubMed ID: 30093324
[TBL] [Abstract][Full Text] [Related]
24. Increased antitumor capability of fiber-modified adenoviral vector armed with TRAIL against bladder cancers.
Zhao Y; Li Y; Wang Q; Wang L; Yang H; Li M
Mol Cell Biochem; 2011 Jul; 353(1-2):93-9. PubMed ID: 21437625
[TBL] [Abstract][Full Text] [Related]
25. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.
Martinez-Velez N; Laspidea V; Zalacain M; Labiano S; García-Moure M; Puigdelloses M; Marrodan L; Gonzalez-Huarriz M; Herrador G; de la Nava D; Ausejo-Mauleon I; Fueyo J; Gomez-Manzano C; Patiño-García A; Alonso MM
Mol Cancer Ther; 2022 Mar; 21(3):471-480. PubMed ID: 34965961
[TBL] [Abstract][Full Text] [Related]
26. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.
Martínez-Vélez N; Xipell E; Vera B; Acanda de la Rocha A; Zalacain M; Marrodán L; Gonzalez-Huarriz M; Toledo G; Cascallo M; Alemany R; Patiño A; Alonso MM
Clin Cancer Res; 2016 May; 22(9):2217-25. PubMed ID: 26603261
[TBL] [Abstract][Full Text] [Related]
27. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
[TBL] [Abstract][Full Text] [Related]
28. Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect.
Wang SB; Tan Y; Lei W; Wang YG; Zhou XM; Jia XY; Zhang KJ; Chu L; Liu XY; Qian WB
Hum Gene Ther; 2012 Sep; 23(9):992-1002. PubMed ID: 22530834
[TBL] [Abstract][Full Text] [Related]
29. Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL.
Burroughs KD; Kayda DB; Sakhuja K; Hudson Y; Jakubczak J; Bristol JA; Ennist D; Hallenbeck P; Kaleko M; Connelly S
Cancer Gene Ther; 2004 Feb; 11(2):92-102. PubMed ID: 14730331
[TBL] [Abstract][Full Text] [Related]
30. Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis.
Hu J; Wang H; Gu J; Liu X; Zhou X
Acta Biochim Biophys Sin (Shanghai); 2018 Oct; 50(10):1018-1027. PubMed ID: 30137199
[TBL] [Abstract][Full Text] [Related]
31. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.
Li G; Kawashima H; Ogose A; Ariizumi T; Xu Y; Hotta T; Urata Y; Fujiwara T; Endo N
J Cancer Res Clin Oncol; 2011 Jun; 137(6):1037-51. PubMed ID: 21193997
[TBL] [Abstract][Full Text] [Related]
32. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
[TBL] [Abstract][Full Text] [Related]
33. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases.
Graat HC; van Beusechem VW; Schagen FH; Witlox MA; Kleinerman ES; Helder MN; Gerritsen WR; Kaspers GJ; Wuisman PI
Mol Cancer; 2008 Jan; 7():9. PubMed ID: 18215325
[TBL] [Abstract][Full Text] [Related]
34. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
Morales-Molina A; Gambera S; Leo A; García-Castro J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
36. Synergistic Suppression Effect on Tumor Growth of Colorectal Cancer by Combining Radiotherapy With a TRAIL-Armed Oncolytic Adenovirus.
Gao H; Zhang X; Ding Y; Qiu R; Hong Y; Chen W
Technol Cancer Res Treat; 2019; 18():1533033819853290. PubMed ID: 31138083
[TBL] [Abstract][Full Text] [Related]
37. Biosilicified oncolytic adenovirus for cancer viral gene therapy.
Kong H; Zhao R; Zhang Q; Iqbal MZ; Lu J; Zhao Q; Luo D; Feng C; Zhang K; Liu X; Kong X
Biomater Sci; 2020 Oct; 8(19):5317-5328. PubMed ID: 32779647
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.
Zhu W; Zhang H; Shi Y; Song M; Zhu B; Wei L
Cancer Biol Ther; 2013 Nov; 14(11):1016-23. PubMed ID: 24025362
[TBL] [Abstract][Full Text] [Related]
39. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
40. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer.
Ge Y; Lei W; Ma Y; Wang Y; Wei B; Chen X; Ru G; He X; Mou X; Wang S
Mol Med Rep; 2017 Jun; 15(6):3521-3528. PubMed ID: 28440486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
